ORAL Presentations - TUESday, June 17

Tuesday June 17

Roosevelt Room

10:45-12:15	OR028 - ASSESSING QUALITY OF LIFE AND IMPLICATIONS FOR PATIENT CARE Moderator: Gunhild Hagen, Norway
10:45	OR28.1 - Brazilian Valuation of EQ-5D Health States- Results from QALYBrasil Project Marisa Santos, Brazil
11:00	OR28.2 - Does the socioeconomic status influence HRQOL preferences? Results from QALYBrasil Project Luis Antonio Diego, Brazil
11:15	OR28.3 - Getting the right focus in economic assessment of telemedicine in HTA Kristian Kidholm, Denmark
11:30	OR28.4 - Efficacy and safety of biologics in the treatment of moderate to severe psoriasis: A Mixed-Treatment Comparison Meta-analysis Cassyano Correr, Brazil
11:45	OR28.5 - Reporting of QALY estimation in applied and published cost-effectiveness analyses Gunhild Hagen, Norway
12:00	OR28.6 - From the minimum clinically important difference to the minimum cost effective difference for EQ-5D in patients with chronic widespread pain Silvia Coretti, Italy

Tuesday June 17

Cabin John Room

10:45-12:15	OR029 - PATIENT-CENTERED CARE #2 Moderator: Helene Karcher, United Kingdom
10:45	OR29.1 - Assessing the impact of changes in patient management and therapy sequences using an early decision model Helene Karcher, United Kingdom
11:00	OR29.2 - Intervention, improvement and impact: the NPS MedicineWise evaluation approach Karen Kaye, Australia
11:15	OR29.3 - Facilitating a patient-centered approach to medication adherence among Type 2 Diabetes patients: differences between patient and provider understandings of information requirements Francesca Katherine Brundisini, Canada
11:30	OR29.4 - Arthroplasty for hip fracture in Uruguay. Earlier surgery and better general care rather than new devices Alarico Rodriguez, Uruguay
11:45	OR29.5 - Patient reported outcomes in diabetic patients in Slovenia Eva Turk, Norway
12:00	OR29.6 - Does postoperative management of patients with obstructive sleep apnea required routine admission to an intensive care unit? Marc Rhainds, Canada

Tuesday June 17

Renwick + Bulfinch Room

10:45-12:15	OR030 - EVALUATING TREATMENT OPTIONS (OF SELECTED CONDITIONS) Moderators: Pwee Keng Ho, Singapore & Christa Harstall, Canada
10:45	OR30.1 - Cost-utility analysis of adalimumab, etanercept and infliximab for the treatment psoriatic arthritis Nicolas Rodrigo Gonzalez-Vacarezza, Uruguay
11:00	OR30.2 - Fingolimod versus natalizumab in Multiple Sclerosis (MS): an indirect treatment comparison Ivan Ricardo Zimmermann, Brazil
11:15	OR30.3 - Interventions to treat premature ejaculation: methods for a rapid review and meta-analysis Marrissa Martyn-St James, United Kingdom
11:30	OR30.4 - Bubble  humidifiers in low-flow oxygen therapy: effectiveness and cost Iñaki Gutierrez-Ibarluzea, Spain
11:45	OR30.5 - Clinical Effectiveness and Safety of Robot Assisted Radical Prostatectomy versus Laparoscopic Radical Prostatectomy: Using Systematic Review Approach Seon-Heui Lee, Korea
12:00	OR30.6 - Patient and household costs associated with a tuberculosis treatment under DOTS strategy in Colombia Gustavo Gonzalez, Colombia

Tuesday June 17

Latrobe Room

10:45-12:15	OR031 - HTA BEST PRACTICES  Moderator: Finn Borlum-Kristensen, Denmark
10:45	OR31.1 - HTA process in updating the catalogs of essential health technologies: lessons learned Rosa Maria Galindo Suarez, Mexico
11:00	OR31.2 - Economic Evaluation of Health Technologies: a checklist for critical assessment Everton Nunes Silva, Brazil
11:15	OR31.3 - Upgrading and extending the possibilities of the HTA Core Model ® Marjukka Mäkelä, Finland
11:30	OR31.4 - Keeping up to date with information retrieval research: Summarized Research in Information Retrieval for HTA (SuRe Info) Sari Susanna Ormstad, Norway
11:45	OR31.5 - Is a Consensus Required on Use of Surrogate Parameters in Health Technology Assessments? A Comparison of Recommendations from 8 HTA Agencies (CADTH, G-BA, IQWiG, HAS, NICE, SMC, PBAC and CONITEC) in the Treatment of Hepatitis C with Protease Inhibitors Rito Bergemann, Germany
12:00	OR31.6 - A comparative analysis of the role and impact of Health Technology Assessment Tim Wilsdon, United Kingdom

Tuesday June 17

Burnham Room

10:45-12:15	OR032 - SPECIAL TOPICS IN HTA Moderator: Gert-Jan van der Wilt, The Netherlands
10:45	OR32.1 - Estimation Measure Weighted of Patient Groups Based on Risk Management Ruben Dario Marrugo, Colombia
11:00	OR32.2 - Publication rate for funded NIHR HTA studies: a cohort study Sheila Turner, United Kingdom
11:15	OR32.3 - Low back pain in Brazilian Public Healthcare System: relationship with disability pensions and hospitalizations Bruna Camilo Turi, Brazil
11:30	OR32.4 - The French National Authority for Health’s recommendations to address MoM hip implants survival issue Emmanuelle Fouteau, France
11:45	OR32.5 - The Economy of Repugnance: Theory and Evidence for the Case of Kidney Transplants Giácomo Balbinotto, Brazil

Tuesday June 17

Lafayette Park Room

10:45-12:15	OR033 - DOING MORE WITH LESS: DECISION-MAKING WITH IMPERFECT INFORMATION  Moderators: Wija Oordwijn, The Netherlands & Andres Pichon-Riviere, Argentina
10:45	OR33.1 - Decision Making Under Uncertainty: Coverage with Evidence Development in the Context of Medical Devices Corinna Sorenson, United Kingdom
11:00	OR33.2 - Use of health technology assessment in decision-making processes by the Brazilian Ministry of Health on the incorporation of technologies in the Brazilian Unified National Health System - 2008 to 2010 Flavia Tavares Silva Elias, Brazil
11:15	OR33.3 - Judicialization and Evidence-Based Assessment Ana Perez, Uruguay
11:30	OR33.4 - Quantification of health by scaling similarity judgments Alexander M.M.Arons, Netherlands
11:45	OR33.5 - High Performance in Priority Setting and Resource Allocation Neale Smith, Canada
12:00	OR33.6 - Prioritizing Topics for HTA in the Republic of the Kazakhstan Lyazzat Kosherbayeva, Kazakhstan

Tuesday June 17

Franklin Square Room

10:45-12:15	OR034 - VARYING USES OF HTA Moderators: Laura Sampietro Colom, Spain & Bjorn Hofmann, Norway
10:45	OR34.1 - How local HTA support decision making: experience from the CHU de Québec Marc Rhainds, Canada
11:00	OR34.3 - Who should receive vocationally oriented multidisciplinary intervention for work ability? Iris Pasternack, Finland
11:15	OR34.4 - Five years of the Brazilian Network for Health Technology Assessment (REBRATS) Indyara Araújo Morais, Brazil
11:30	OR34.5 - Occupational physical activity and economic losses due to absenteeism: Case of Brazilian Public Healthcare System Jamile Sanches Codogno, Brazil
11:45	OR34.6 - Bariatric Surgery Access Across Global Markets: Are Clinical Guidelines and HTA Requirements Aligned? Amarpreet S Chawla, USA

Tuesday June 17

McPherson Square Room

10:45-12:15	OR035 - INTERESTING INNOCULATIONS: VACCINES AND PREVENTIVE HEALTH TOPICS Moderator: Inaki Gutierrez-Ibarluzea, Spain
10:45	OR35.1 - Cost-effectiveness of a HPV-vaccination catch-up program for females up to 26 years old in a Norwegian setting Enrique Jimenez, Norway
11:00	OR35.2 - Quadrivalent HPV vaccine in Argentina: cost-effectiveness analysis Andrea Alcaraz, Argentina
11:15	OR35.3 - Immunochemical Fecal Occult Blood Testing: Determination of an Effective Cut-Off Value for Quebec’s Colorectal Cancer Screening Program when the Colonoscopy Capacity is Limited Eric Potvin, Canada
11:30	OR35.4 - The strategies to the HPV vaccine implementation in Brazil Avila Teixeira Vidal, Brazil
11:45	OR35.5 - Cost effectiveness analysis of a vaccine to prevent herpes zoster and postherpetic neuralgia in Italy Silvia Coretti, Italy
12:00	OR35.6 - Economic Impact of Alberta’s PCV7 Childhood Immunization Program (2003-2008) Arianna Waye, Canada

Tuesday June 17

Roosevelt Room

15:45-17:15	OR036 - TREATMENT ALGORITHMS AND PROTOCOLS  Moderators: Andrew Bruce, Switzerland & Debjani Mueller, South Africa
15:45	OR36.1 - Diagnosing carpal tunnel syndrome with hand-held nerve conduction device Marjukka Mäkelä, Finland
16:00	OR36.2 - Assessing the Value of a Comprehensive Model of Care for the Treatment of Hemophilia a in Colombia Rafael Alfonso-Cristancho, USA
16:15	OR36.3 - Systematic Critical Review of Economic Evaluations of the Elimination of H. pylori for Gastric Cancer Prevention Arianna Waye, Canada
16:30	OR36.4 - Accuracy of a Dengue Imunochromatographic Strip Test in a Predominant DENV 4 Setting Sibelle N Buonora, Brazil
16:45	OR36.5 - Biochemical characterization of a sample of Brazilian patients with mucolipidosis II / III and a purpose of diagnostic protocol Ida Vanessa Doederlein Schwartz, Brazil

Tuesday June 17

Cabin John Room

15:45-17:15	OR037 - ECONOMIC EVALUATIONS OF CARDIOVASCULAR THERAPIES  Moderator: Giacomo Balbinotto, Brazil
15:45	OR37.2 - Cost-effectiveness of electroconvulsive therapy compared to repetitive transcranial magnetic stimulation for treatment–resistant severe depression: a decision model Laura Vallejo-Torres, Spain
16:00	OR38.2 - Evaluation of the Routine Use of Cintigraphy to Detect Bone Metastases in Patients with Hepatocellular Carcinoma in the Waiting List for Liver Transplantation Giácomo Balbinotto, Brazil
16:15	OR37.4 - Rhythm Control versus Rate Control for Atrial Fibrillation: A Comparison of Economic Costs Meng Tang, China
16:30	OR37.5 - Comparison of Off-Pump and On-Pump Coronary Artery Bypass Graft(CABG) in Korea Yeonhee Cho, Korea
16:45	OR37.6 - An empirical study comparing health technology assessment reports for drugs versus medical devices in the field of cardiovascular disease Britni Wilcher, United Kingdom

Tuesday June 17

Renwick + Bulfinch Room

15:45-17:15	OR038 - SPECIAL TOPICS IN ONCOLOGY Moderators: Deborah Marshall, Canada & Gro Jamtvedt, Norway
15:45	OR38.1 - Efficacy, cost-effectiveness and budget impact: temozolomide plus radiotherapy in adjuvant treatment of patients with high-grade gliomas Adriana Camargo Carvalho, Brazil
16:00	OR38.4 - The value of personalizing medicine: Medical oncologists’ views on gene expression profiling in breast cancer treatment Yvonne Bombard, Canada
16:15	OR38.3 - Health economic evaluation of bevacizumab in patients with metastatic colorectal cancer in Argentina Victoria Wurcel, Argentina
16:45	OR38.5 - Surrogate vs final outcomes: comparison of effect sizes from a meta-analysis of RCTs in metastatic colorectal cancer Oriana Ciani, United Kingdom
17:00	OR38.6 - The Impact of NICE’s End-of-Life Threshold on the Availability of New Cancer Therapies in England and Wales Gavin Stewart, United Kingdom

Tuesday June 17

Latrobe Room

15:45-17:15	OR039 - HTA AROUND THE WORLD: REGIONAL INSIGHTS Moderators: David Banta, France & Jeonghoon Ahn, Korea
15:45	OR39.1 - Budget impact analisys for support decision-making: case of the Bevacizumab in Brazilian Health System Flávia Tavares Silva Elias, Brazil
16:00	OR39.2 - HTA knowledge translation in China: from the perspective of researchers with the major of medicine and non-medicine Maoling Wei, China
16:15	OR39.3 - Kazakhstan's Benefits from collaboration with NICE Temirkhan Kulkhan, Kazakhstan
16:30	OR39.5 - HTA of adalimumab for rheumatoid arthritis in Germany Christian Gissel, Germany

Tuesday June 17

Burnham Room

15:45-17:15	OR040 - CHECKS AND BALANCES: IMPLICATIONS OF HTA ON INNOVATION Moderators: Mitchell Sugarman, USA & Sarcashni Moodliar, South Africa
15:45	OR40.1 - HTA: hampering or guiding innovation? Bjørn Hofmann, Norway
16:00	OR40.2 - Parallel Review System of New Health Technology For The Early Introduction In Clinical Field Sejung Kim, Korea
16:15	OR40.4 - Is horizon scanning in accordance with demanded health technological innovations? Leonor Varela-Lema, Spain
16:30	OR40.5 - Early assessment of new technologies: the case of whole exome sequencing as a diagnostic tool in complex pediatric neurology Kirsten van Nimwegen, Netherlands
16:45	OR40.6 - Developing a primary submission process to promote early assessment and adoption of promising non-medicine technologies Susan Myles, United Kingdom

Tuesday June 17

Lafayette Park Room

15:45-17:15	OR041 - ECONOMIC CONSIDERATIONS OF METABOLIC SYNDROMES  Moderator: Mike Chambers, United Kingdom
15:45	OR41.2 - Using childhood obesity to predict adult morbidity: a systematic review Alexis Llewellyn, United Kingdom
16:00	OR41.3 - The Agency for Healthcare Research & Quality’s (AHRQ) “Methods for Insulin Delivery and Glucose Monitoring: Comparative Effectiveness” results revisited regarding randomized trials comparing of real-time Continuous Glucose Monitoring (rt-CGM) versus Self Monitoring of Blood Glucose (SMBG) stratified for different insulin delivery modes Karsten Berndt, Germany
16:15	OR41.4 - Budget impact analysis of insulin analogues for type 1 diabetes: the case of Brazilian Public Health System Clarice Alegre Petramale, Brazil
16:30	OR41.5 - Key influencing parameters of a research protocol: the Agency for Healthcare Research & Quality’s (AHRQ) “Methods for Insulin Delivery and Glucose Monitoring: Comparative Effectiveness” review protocol revisited Karsten Berndt, Germany
16:45	OR41.6 - The impact of an imperfect diagnostic reference standard on the cost-effectiveness of HbA1c testing in the diagnosis of Type II diabetes Camille Schubert, Australia

Tuesday June 17

Franklin Square Room

15:45-17:15	OR042 - HOSPITAL-BASED HTA #3 Moderators: Claudia Wild, Austria & Kristian Kidholm, Denmark
15:45	OR42.1 - Hospital based HTA in the Republic of Kazakhstan Lyazzat Kosherbayeva, Kazakhstan
16:00	OR42.2 - The role of Hospital Based Health Technology Assessment in the uptake of health technologies: evidence from AdHopHTA Americo Cicchetti, Italy
16:15	OR42.3 - Advancing health technology assessment in Finnish Hospitals Risto Roine, Finland
16:30	OR42.4 - Collaboration between hospitals and national HTA agency in Finland Esa Halmesmäki, Finland
16:45	OR42.5 - Collaboration between hospitals and HTA agencies: facilitators and barriers Iris Pasternack, Finland
17:00	OR42.6 - Results of a 13-year hospital-based HTA program in a public pediatric hospital in Argentina Graciela Beatriz Demirdjian, Argentina

Tuesday June 17

McPherson Square Room

15:45-17:15	OR043 - UNIQUE PERSPECTIVES ON HTA Moderators: Rabia Kahveci, Turkey & Jim Murray, USA
15:45	OR43.1 - HTA of Critical Information System Anesthesia (CIS AN) Mette Frydensbjerg Bøg, Denmark
16:00	OR43.2 - Drug negotiation in a HTA perspective: experiences and expectations among stakeholders Marco Marchetti, Italy
16:15	OR43.3 - The clinical relevance and newsworthiness of UK NIHR HTA funded research David Wright, United Kingdom
16:30	OR43.4 - A taxonomy of medical devices in the logic of HTA Dimitra Panteli, Germany
16:45	OR43.5 - Technology Assessment at the service of the Brazilian Public Health System (SUS) Isadora Fernandez Patterson, Brazil
17:00	OR43.6 - Challenges to Establish a Health Technology Assessment (HTA) Unit in Cipto Mangunkusumo Hospital Siti Rizny F.Saldi, Indonesia